p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy - Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., Tinsley, R., Eng, M., Wilczynski, S., Ellenhorn, J. D. I., Diamond, D. J., Cristea, M. (The American Association for Cancer Research (AACR), 2018)
6208027